Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$68.70
-0.30 (-0.43%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $44.5M · quality 46.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.1B
P/E
N/A
•EV/EBITDA
382.9x
↑ROE
-2.2%
↓Gross Margin
56.3%
↑Debt/Equity
1.26
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.1%
FCF CAGR
—
FCF margin
-0.8%
FCF / Net income
0.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $511.8M · net income $-10.3M · FCF $-4.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $511.8M | $511.8M | $385.2M | $460.0M | $528.5M |
| Net Income | $-10.3M | $-10.3M | $11.7M | $17.7M | $59.5M |
| EBITDA | $9.5M | $9.5M | $25.5M | $31.0M | $72.1M |
| EPS | — | — | 0.26 | 0.39 | 1.30 |
| Gross Margin | 56.3% | 56.3% | 59.7% | 62.2% | 63.7% |
| Operating Margin | -3.2% | -3.2% | 0.2% | 4.1% | 11.0% |
| Net Margin | -2.0% | -2.0% | 3.0% | 3.9% | 11.3% |
| Balance Sheet | |||||
| Debt/Equity | 1.26 | 1.26 | 0.72 | 0.17 | 0.24 |
| Current Ratio | 0.44 | 0.44 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.1M | $-4.1M | $44.5M | $64.3M | $20.9M |
| Returns | |||||
| ROE | -2.2% | -2.2% | 2.4% | 3.6% | 12.5% |
| Valuation | |||||
| P/E | — | — | 158.46 | 36.79 | 11.19 |
| EV/EBITDA | 382.94 | 382.94 | 82.39 | 19.31 | 9.32 |
| P/B | 6.63 | 6.63 | 3.95 | 1.33 | 1.40 |
| Growth & Yield | |||||
| Revenue Growth | 32.9% | 32.9% | -16.3% | -13.0% | — |
| EPS Growth | — | — | -33.3% | -70.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+81.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.26 → n/d
Residual
+81.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.